Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Notes Payables: 2011-2020

Historic Notes Payables for Heron Therapeutics (HRTX) over the last 7 years, with Dec 2020 value amounting to $7.1 million.

  • Heron Therapeutics' Notes Payables was N/A to $149.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $149.8 million, marking a year-over-year change of. This contributed to the annual value of $7.1 million for FY2020, which is 25.41% up from last year.
  • Heron Therapeutics' Notes Payables amounted to $7.1 million in FY2020, which was up 25.41% from $5.6 million recorded in FY2019.
  • Heron Therapeutics' 5-year Notes Payables high stood at $25.0 million for FY2017, and its period low was $2.9 million during FY2016.
  • For the 3-year period, Heron Therapeutics' Notes Payables averaged around $5.8 million, with its median value being $5.6 million (2019).
  • Per our database at Business Quant, Heron Therapeutics' Notes Payables spiked by 758.81% in 2017 and then plummeted by 81.70% in 2018.
  • Heron Therapeutics' Notes Payables (Yearly) stood at $2.9 million in 2016, then skyrocketed by 758.81% to $25.0 million in 2017, then crashed by 81.70% to $4.6 million in 2018, then grew by 22.96% to $5.6 million in 2019, then increased by 25.41% to $7.1 million in 2020.